276 related articles for article (PubMed ID: 36517926)
1. Exploring the question of financial incentives for training amongst non-adopters of MOUD in rural primary care.
Haggerty T; Turiano NA; Turner T; Dekeseredy P; Sedney CL
Addict Sci Clin Pract; 2022 Dec; 17(1):72. PubMed ID: 36517926
[TBL] [Abstract][Full Text] [Related]
2. Opioid use-related stigma and health care decision-making.
Brown RL; Batty E; Lofwall M; Kiviniemi M; Kizewski A
Psychol Addict Behav; 2023 Mar; 37(2):222-227. PubMed ID: 35343742
[TBL] [Abstract][Full Text] [Related]
3. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
Jaffe K; Slat S; Chen L; Macleod C; Bohnert A; Lagisetty P
J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
[TBL] [Abstract][Full Text] [Related]
4. Attitudes toward and training in medications for opioid use disorders: a descriptive analysis among employees in the youth legal system and community mental health centers.
O'Reilly LM; Schwartz K; Brown SA; Dir A; Gillenwater L; Adams Z; Zapolski T; Hulvershorn LA; Aalsma M
Subst Abuse Treat Prev Policy; 2024 Jun; 19(1):32. PubMed ID: 38907286
[TBL] [Abstract][Full Text] [Related]
5. Psychometric evaluation of two indices assessing stigma toward opioid misuse and treatment among health care providers.
Brown RL; Batty E; Lofwall M; Kiviniemi M; Kizewski A
Am J Drug Alcohol Abuse; 2022 Mar; 48(2):158-164. PubMed ID: 35100062
[No Abstract] [Full Text] [Related]
6. From policy to practice: Pilot program increases access to medication for opioid use disorder in rural Colorado.
Sorrell TR; Weber M; Alvarez A; Beste N; Hollins U; Amura CR; Cook PF
J Subst Abuse Treat; 2020 Jul; 114():108027. PubMed ID: 32527514
[TBL] [Abstract][Full Text] [Related]
7. Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives.
Kelley AT; Wilcox J; Baylis JD; Crossnohere NL; Magel J; Jones AL; Gordon AJ; Bridges JFP
J Gen Intern Med; 2023 Jul; 38(9):2147-2155. PubMed ID: 36471194
[TBL] [Abstract][Full Text] [Related]
8. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
Madden EF; Prevedel S; Light T; Sulzer SH
Subst Use Misuse; 2021; 56(14):2181-2201. PubMed ID: 34538213
[TBL] [Abstract][Full Text] [Related]
9. Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
Pasman E; Lee G; Kollin R; Rodriguez B; Agius E; Madden EF; Resko SM
Subst Use Misuse; 2022; 57(12):1828-1836. PubMed ID: 36041008
[No Abstract] [Full Text] [Related]
10. Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.
Franz B; Dhanani LY; Hall OT; Brook DL; Simon JE; Miller WC
Harm Reduct J; 2023 Dec; 20(1):180. PubMed ID: 38129903
[TBL] [Abstract][Full Text] [Related]
11. Assessing waivered and non-waivered physician barriers to treating patients with substance use disorders: a cross-sectional Kentucky pilot.
Thompson RA; Johnson D; Kizewski AL; Baier L; Coburn K; White J; Bunn T; Fletcher EL
J Addict Dis; 2022; 40(4):518-526. PubMed ID: 35238283
[TBL] [Abstract][Full Text] [Related]
12. Association of MOUD ECHO Participation on Expansion of Buprenorphine Prescribing in Rural Primary Care.
Salvador JG; Myers OB; Bhatt SR; Jacobsohn V; Lindsey L; Alkhafaji RS; Rishel Brakey H; Sussman AL
Subst Abus; 2023 Oct; 44(4):282-291. PubMed ID: 37902036
[TBL] [Abstract][Full Text] [Related]
13. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives.
Michener PS; Evans EA; Ferguson WJ; Friedmann PD
Addict Sci Clin Pract; 2024 Feb; 19(1):10. PubMed ID: 38347634
[TBL] [Abstract][Full Text] [Related]
14. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
Andraka-Christou B; Atkins D
Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
[TBL] [Abstract][Full Text] [Related]
15. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
[TBL] [Abstract][Full Text] [Related]
16. Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.
Andraka-Christou B; Page C; Schoebel V; Buche J; Haffajee RL
Addict Sci Clin Pract; 2022 Aug; 17(1):43. PubMed ID: 35945636
[TBL] [Abstract][Full Text] [Related]
17. Impact of Stigma on Clinician Training for Opioid Use Disorder Care: A Qualitative Study in a Primary Care Learning Collaborative.
Klusaritz H; Bilger A; Paterson E; Summers C; Barg FK; Cronholm PF; Saine ME; Sochalski J; Doubeni CA
Ann Fam Med; 2023 Feb; 21(Suppl 2):S31-S38. PubMed ID: 36849482
[TBL] [Abstract][Full Text] [Related]
18. Empowering Psychiatric Mental Health Nurse Practitioners to Expand Treatment Opportunities for Veterans With Opioid Use Disorder.
Jones J; Tierney M; Jacobs G; Chien SY; Mallisham S
J Addict Nurs; 2020; 31(4):261-268. PubMed ID: 33264198
[TBL] [Abstract][Full Text] [Related]
19. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
Cioe K; Biondi BE; Easly R; Simard A; Zheng X; Springer SA
J Subst Abuse Treat; 2020 Dec; 119():108146. PubMed ID: 33138929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
